Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315369 | 0.85 | MAPK1 (0.41) | MAPK1MEN1KMT2ATDP1CYP19A1 | |
| SCHEMBL3266419 | 0.85 | MAPK1 (0.40) | MAPK1GRM2MEN1KMT2AUSP2 | |
| SCHEMBL2172173 | 0.83 | KDM4E (0.52) | MAPK1MEN1KMT2AUSP2TSHR | |
| SCHEMBL3237661 | 0.83 | MAPK1 (0.40) | MAPK1GRM2MEN1KMT2ACYP19A1 | |
| SCHEMBL3238214 | 0.83 | MAPK1 (0.39) | MAPK1GRM2 | |
| SCHEMBL3233026 | 0.82 | MAPK1 (0.51) | MAPK1GRM2MEN1KMT2AUSP2 | |
| SCHEMBL2161013 | 0.81 | MAPK1 (0.52) | MAPK1MEN1KMT2AUSP2TSHR | |
| SCHEMBL3230953 | 0.78 | MAPK1 (0.51) | MAPK1MEN1KMT2AUSP2TSHR | |
| SCHEMBL2170834 | 0.78 | GRM2 (0.37) | MAPK1GRM2TDP1L3MBTL1CXCR2 | |
| SCHEMBL3232870 | 0.77 | SMN1; SMN2 (0.45) | KMT2ATSHRHSD17B10L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190122-A1 | Triazole and Imidazole Compounds, Use Thereof and Agents Containing Them | BASF SE (DE) | 2011-08-04 | — | — | US | disclosed |
| EP-2346839-A1 | TRIAZOLE AND IMIDAZOLE COMPOUNDS, USE THEREOF AND AGENTS CONTAINING THEM | BASF SE (DE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010040717-A1 | TRIAZOLE AND IMIDAZOLE COMPOUNDS, USE THEREOF AND AGENTS CONTAINING THEM | BASF SE (DE) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190122-A1 | Triazole and Imidazole Compounds, Use Thereof and Agents Containing Them | ABAT, OAT, TYR | MAPK1 1624/4885GRM2 4587/4885MEN1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.